The company is exploring alternative methods of administering GLP-1 medications beyond injectables, with the goal of achieving scalable production to reach a wider population, says Karla Alczar, President and General Manager, Lilly Latin America, during Mexico Health Summit 2025.
She says the company has additionally filed three lawsuits against compounders for improper marketing practices and using an unsafe version of tirzepatide, and she pointed toward an FDA warning letter against a compounding pharmacy in California that recently shut down after a bad inspection
Thats why we created Nooms GLP-1 Companion and Noom Med programs
Most of them fall under the category of overweight/obesity or type 2 diabetes, but theres a few I found by accident I think will be VERY interesting to see in the near future
Our team strongly recommends [Bacteriostatic Water]( for multi-use vials as it contains a preservative to prevent bacterial growth
doi:10.1016/j.drudis.2021.07.009